The appropriate clinical use of niacin in the treatment of dyslipidemia

References

• Effects of extended-release niacin with laropiprant in high-risk patients. The HPS2-THRIVE collaborative group. N. Engl. J. Med. 371, 203–212 (2014). • This is an important study that indicates that potential hazards of adding a drug with an unknown biological and clinical side effect profile and an unknown efficacy in prevention and treatment of cardiovascular disease (CVD) to a proven therapy such as niacin.
   Google Scholar
• Lai E, De Lepeleire I, Crumley TM et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin. Pharmacol. Ther. 81(6), 849–857 (2007).
   Google Scholar
• Lai E, Wenning LA, Crumley TM et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin. Pharmacol. Ther. 83(6), 840–847 (2008).
   Google Scholar
• NLA Statement on Use of Niacin in Light of HPS2-THRIVE Presentation on 9 March (2013). www.NLA.org
   Google Scholar
• Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 8(6), 1245–1255 (1986). • Excellent review and discussion of the long-term use of niacin in the prevention and treatment of cardiovascular disease and total mortality. significant reductions in cardiovascular events and mortality were found.
   Google Scholar
• Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J. Am. Coll. Cardiol. 61(4), 440–446. (2013). • One of the best recent meta-analysisof niacin in cardiovascular disease that indicates excellent clinical outcomes.
   Google Scholar
• Franceschini G, Favari E, Calabresi L et al. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients. J. Clin. Lipidol. 7(5), 414–422 (2013).
   Google Scholar
• Yang YL, Hu M, Chang M, Tomlinson B. A high incidence of exanthematous eruption associated with niacin/ laropiprant combination in Hong Kong Chinese patients. J. Clin. Pharm. Ther. 38(6), 528–532 (2013).
   Google Scholar
• Ong KL, Barter PJ, Waters DD. Cardiovascular drugs that increase the risk of new-onset diabetes. Am. Heart J. 167(4), 421–428 (2014).
   Google Scholar
• Waters DD, Ho JE, DeMicco DA et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J. Am. Coll. Cardiol. 57(14), 1535–1545 (2011).
   Google Scholar
• Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375(9716), 735–742 (2011). • Statins are known to increase the incidence of type 2 diabetes mellitus. this meta-analysis provides insight into the clinical use of statins related to diabetes, the risk benefit and some comparative data related to niacin therapy.
   Google Scholar
• Doneen A, Bale B. Niacin. Throwing the baby out with the bathwater? J. Arteriol. 22, 1–4 (2012 ). www.baledoneen.com
   Google Scholar
• De Kam PJ, Luo WL, Wenning L et al. The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin. Platelets 25(7), 480–487 (2014).
   Google Scholar
• Labrecque P, Roy SJ, Fréchette L, Iorio-Mori C, Gallant MA, Parent JL. Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptor. PLoS ONE 8(6), e65767 (2013).
   Google Scholar
• AIM-HIGH Investigators, Boden WE, Probstfield JL et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365(24), 2255–2267 (2011).
   Google Scholar
• Hovsepian E, Penas F, Goren NB. 15-deoxy-delta12,14 prostaglandin GJ2 but not rosiglitazone regulates metalloproteinase 9, NOS-2, and cyclooxygenase 2 expression and functions by peroxisome proliferator-activated receptor gamma-dependent and independent mechanisms in cardiac cells. Shock 34(1), 60–67 (2010). • Prostaglandin G J2, a metabolite of prostaglandin D2 may have numerous therapeutic effects in the prevention and treatment of cardiovascular disease. balance of prostaglandin receptor stimulation or antagonism may alter these metabolites.
   Google Scholar
• Kansanen E, Kivelä AM, Levonen AL. Regulation of Nrf2-dependent gene expression by 15-deoxy-delta12, 14-prostaglandin J2. Free Radic. Biol. Med. 47(9), 1310–1317 (2009).
   Google Scholar
• Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem. Pharmacol. 67(3), 411–419 (2004).
   Google Scholar
• Morrow JD, Parsons WG 3rd, Roberts LJ 2nd. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 38(2), 263–274 (1989). • Excellent review of the role of prostaglandin D2 in the efficacy of niacin in the prevention and treatment of cardiovascular disease. an increase in prostaglandin D2 and the receptor mediated effects are important in both the adverse events and efficacy of niacin.
   Google Scholar
• Otvos JD. The surprising AIM-HIGH results are not surprising when viewed through a particle lens. J. Clin. Lipidol. 5(5), 368–370 (2011).
   Google Scholar
• Taylor AJ, Villines TC, Stanek EJ et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 361(22), 2113–2122 (2009).
   Google Scholar
• Hochholzer W, Berg DD, Giugliano RP. The facts behind niacin. Ther. Adv. Cardiovasc. Dis. 5(5), 227–240 (2011).
   Google Scholar
• Lee JM, Robson MD, Yu LM et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J. Am. Coll. Cardiol. 54(19), 1787–1794 (2009).
   Google Scholar
• Al-Mohaissen MA, Pun SC, Frohlich JJ. Niacin: from mechanisms of action to therapeutic uses. Mini. Rev. Med. Chem. 10(3), 204–217 (2010).
   Google Scholar
• Phan BA, Muñoz L, Shadzi P et al. Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study. Am. J. Cardiol. 111(3), 352–355 (2013).
   Google Scholar
• Toth PP, Thakker KM, Jiang P, Padley RJ. Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy. Vasc. Health Risk Manag. 8, 39–44 (2012).
   Google Scholar